Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

American Medical Association fact sheet on ocrelizumab
Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis.
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Mycophenolate mofetil in multiple sclerosis.
Experimental autoimmune encephalomyelitis in the mouse.
Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial.
Harry Lee Parker and paroxysmal dysarthria and ataxia.
Mouse models for multiple sclerosis: historical facts and future implications.
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.
Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
Precision medicine in chronic disease management: The MS BioScreen.
Rapidly progressive cerebellar ataxia in West Wales.
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
CellCept (Product Insert)
Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.
CellCept Drug Details
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

Pages